Get started
Author

Helen L. Stacey

Observed names: H. Stacey, Helen L Stacey, Helen Lee Stacey, Helen Stacey
ORCID: 0000-0003-1919-0302
Observed ORCID: 0000-0003-1919-0302
OpenAlex ID: A5013046560
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
2021 · Stefano Del Prato, Steven E Kahn, et al. · The Lancet · 749
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults
2019 · Helen L. Stacey, Jeffrey Rosen, et al. · Human Vaccines & Immunotherapeutics · 110
PDF
Safety and tolerability of KAN-101, a liver-targeted immune tolerance therapy, in patients with coeliac disease (ACeD): a phase 1 trial
2023 · Joseph A Murray, Dina Wassaf, et al. · The Lancet. Gastroenterology & hepatology · 64
Baseline quantitative histology in therapeutics trials reveals villus atrophy in most patients with coeliac disease who appear well controlled on gluten‐free diet
2019 · A. James M. Daveson, Alina Popp, et al. · GastroHep · 64
PDF
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
2018 · James T. Peterson, Helen L. Stacey, et al. · Human Vaccines & Immunotherapeutics · 54
PDF
A Phase 3 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine–Experienced Adults 50 Years of Age or Older (STRIDE-6)
2024 · Paul Scott, Miwa Haranaka, et al. · Clinical Infectious Diseases · 46
Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study
2023 · Jason A Tye-Din, A James M Daveson, et al. · The Lancet. Gastroenterology & hepatology · 42
Bivalent RSVpreF Vaccine in Adults 18 to <60 Years Old With High-Risk Conditions
2024 · Matthew Davis, William Towner, et al. · Clinical Infectious Diseases · 29
A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds
2023 · Lisa Usdan, Sohil Patel, et al. · Clinical Infectious Diseases · 20
PDF
Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age
2025 · Joel M. Neutel, Rahsan Erdem, et al. · Vaccines · 12
PDF
Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18–49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years
2026 · Essack Mitha, Murdo Ferguson, et al. · Clinical Infectious Diseases · 7
571. Safety and Immunogenicity of Coadministered Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine With and Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age
2025 · Joel Neutel, Rahsan Erdem, et al. · Open Forum Infectious Diseases · 1
Late Breaking Abstract - Immunogenicity and safety of AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (adjuvanted RSVPreF3) up to 6 months post-vaccination in adults 18–49 years of age (YOA) at increased risk of RSV disease and adults ≥60 YOA
2025 · Essack Mitha, Murdo Ferguson, et al. · European Respiratory Journal
1634. Respiratory Syncytial Virus-Associated Health Care Utilization in the Pivotal Phase 3 Trial RSV Vaccine Efficacy Study In Older Adults Immunized Against RSV Disease (RENOIR)
2023 · Edward E Walsh, Kumar Ilangovan, et al. · Open Forum Infectious Diseases
PDF
1972. Safety and Immunogenicity of 15-Valent Pneumococcal Conjugate Vaccine (PCV-15) Compared with PCV-13 in Healthy Older Adults Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23)
2018 · Ulrike Buchwald, James Peterson, et al. · Open Forum Infectious Diseases
Works count: 16
Citation count: 1,244
H-index: 11
I10-index: 11
Year
Topic
Type